Ozempic vs Zepbound
Semaglutide vs Tirzepatide — Complete Comparison (2026)
Ozempic (semaglutide) is a GLP-1 injection branded for type 2 diabetes; Zepbound (tirzepatide) is a dual GLP-1/GIP injection branded for obesity. People compare them constantly for weight loss. Here's how their mechanisms, data, and indications actually differ.
Ozempic vs Zepbound: At a Glance
- ✓GLP-1 receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for type 2 diabetes
- ✓Wegovy is the obesity-branded twin (same drug)
- ✓Strong weight loss and HbA1c reduction
- ✓Novo Nordisk
- ✓Dual GLP-1/GIP receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and sleep apnea
- ✓Mounjaro is the diabetes-branded twin (same drug)
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks
- ✓Eli Lilly
Detailed Comparison
| Feature | Ozempic (Semaglutide) | Zepbound (Tirzepatide) |
|---|---|---|
| Generic | Semaglutide | TirzepatideBest |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Brand Indication | Type 2 diabetes | Obesity / sleep apnea |
| Weight-Loss Twin | Wegovy (semaglutide 2.4 mg) | Zepbound is the obesity brand |
| Administration | Once-weekly injection | Once-weekly injection |
| Weight Loss | Strong (semaglutide; ~15% at 2.4 mg) | ~20.9% at 72 weeks |
| Extra Indications | CV risk reduction (in diabetes) | Obstructive sleep apnea |
| Side Effects | Nausea, vomiting, diarrhea | Nausea, diarrhea, constipation |
| FDA Status | Approved (diabetes 2017) | Approved (obesity 2023) |
How to Choose
Maximum Weight Loss
Tirzepatide (Zepbound) generally produces more weight loss than semaglutide thanks to its dual mechanism — about 20.9% at 72 weeks.
On-Label for Weight
Zepbound is FDA-approved for obesity; Ozempic is approved for diabetes. For weight-loss coverage, the obesity brand matters — that's Zepbound or Wegovy.
Diabetes Control
Both lower blood sugar well. If diabetes is the diagnosis, Ozempic is on-label; the tirzepatide diabetes brand is Mounjaro.
Extra Indication
Zepbound carries an obstructive sleep apnea indication. Ozempic has cardiovascular risk-reduction data in diabetes.
Tolerability
Both cause GI side effects during titration. Individual tolerance varies — some do better on one than the other.
Cost & Access
Both are costly without coverage. Indication-driven insurance rules often decide the real-world choice.
Which Should You Choose?
For weight loss, the data favors tirzepatide (Zepbound): its dual GLP-1/GIP mechanism produced roughly 20.9% weight loss at 72 weeks, more than semaglutide achieves. And because Zepbound is FDA-approved for obesity, it is usually the on-label, coverage-relevant option for weight loss — whereas Ozempic is approved for diabetes.
There is an important brand nuance here. Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). The "weight-loss versions" are Wegovy and Zepbound. Many people end up comparing Ozempic vs Zepbound because Ozempic is the famous name, but for obesity the apples-to-apples comparison is Wegovy vs Zepbound.
If you have diabetes, Ozempic is on-label and effective. If your goal is weight loss, Zepbound has the higher ceiling and the obesity indication. Track your dose, weight, and side effects in Shotlee so you can see your real-world response on whichever you take.
Ozempic vs Zepbound: Frequently Asked Questions
Zepbound (tirzepatide) generally produces more weight loss — about 20.9% at 72 weeks — than semaglutide. It is also FDA-approved for obesity, while Ozempic is approved for diabetes. For weight loss specifically, Zepbound (or Wegovy) is the on-label choice.
Ozempic is semaglutide, a GLP-1 agonist branded for type 2 diabetes. Zepbound is tirzepatide, a dual GLP-1/GIP agonist branded for obesity. Both are once-weekly injections from different companies.
For weight loss, the cleaner comparison is Wegovy vs Zepbound, because those are the obesity-indicated brands. Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide).
For weight loss, yes — a higher weight-loss ceiling and an obesity indication, plus a sleep-apnea indication. Ozempic's strengths are its diabetes track record and cardiovascular data in diabetes.
Yes. Shotlee tracks any GLP-1 — semaglutide and tirzepatide included — with dose logs, weight trends, and side-effect tracking.
Track Ozempic or Zepbound in Shotlee
Free dose logging, weight trends, and side-effect tracking for any GLP-1.
📚References & sources
Latest on Ozempic
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Anandita Sundar's 7-Year Weight Loss Journey and Body Shaming
Anandita Sundar opens up about her seven-year weight loss journey, highlighting the profound impact of body shaming on mental health and her commitment to prioritizing well-being over societal expectations.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read